Navigation Links
Zithromax Arrhythmia and Sudden Death Allegation Claims Now Being Accepted by Resource4thePeople Lawyers
Date:4/5/2013

San Diego, CA (PRWEB) April 05, 2013

http://www.resource4thepeople.com/defectivedrugs/Zithromax-lawsuits.html

Resource4thePeople announced today that its lawyers are now accepting claims from consumers who are alleging they may have suffered serious side effects from treatment with the popular antibiotic Zithromax, which is also sold as azithromycin or as the Z-Pak.

These side effects have been cited in concerns raised by the Food and Drug Administration* and a respected medical journal** over whether patients who use the medications are at higher risk of suffering cardiac problems, said Resource4thePeople.

“The dissemination of information about these concerns has generated a substantial amount of inquiries from concerned consumers who were treated with these popular antibiotics,” said Resource4thePeople.

“Therefore we are announcing that our lawyers are now accepting claims of health problems caused by the use of the antibiotics sold as Zithromax, the Z-Pak and azithromycin.”

Resource4thePeople’s national network of attorneys will now be offering free consultations to those consumers seeking to determine whether they are eligible to file a Zithromax lawsuit.

“We will be able to provide the legal options that may be available, depending upon the facts of each case, for consumers to seek compensation for such expenses as medical costs, pain and suffering, loss of wages and other expenses that may have been incurred,” said Resource4thePeople.

Resource4thePeople has noted a steady increase in Zithromax inquiries since the FDA issued a Safety Information Report* “on risk of cardiovascular death” in connection with the use of Zithromax.

In that report, FDA officials said that they have been made aware of a study** published in the New England Journal of Medicine in which medical researchers found a higher percentage of cardiovascular deaths among patients treated with azithromycin (Zithromax) than with other antibiotics or no drugs.

The FDA announced that it is reviewing the findings of this study and said it will inform health care professionals and consumers about the results of this review after its completion.

The FDA also passed on this information about the review and updated warnings on the medication’s labels about health risks:

“Azithromycin belongs to a class of antibacterial drugs called macrolides, which have been associated with cardiovascular effects; specifically, prolongation of the QT interval. In 2011, FDA reviewed macrolide drug labeling information related to QT interval prolongation and TdP.

“The WARNINGS AND PRECAUTIONS section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March 2012 to include new information regarding risk for QT interval prolongation, which appears to be low.

“The drug labels for clarithromycin and erythromycin also contain information about QT interval prolongation in the WARNINGS section. FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs.”

The FDA also recommended that patients who are taking azithromycin should not stop taking their medicine without talking to their health care professional and that physicians “should be aware of the potential for QT interval prolongation and heart arrhythmias when prescribing or administering macrolides.”

“In its Safety Information Report the FDA also encouraged patients and health care professionals to report adverse events or side effects caused by the use of these medications to the agency,” said Resource4thePeople.

“While the FDA is fulfilling its role of monitoring the safety of drugs such as Zithromax we are responding to reports from patients who are seeking information about what their legal rights may be and we are committed to providing that information on a case-by-case basis.”

The New England Journal of Medicine study** included research compiled from information accumulated from about 350,000 patients who were treated with azithromycin over a 15-year period and concluded that these patients were one and a half times more likely to suffer cardiovascular sudden death than patients treated with other antibiotics.

Antibiotics are among the most prescribed medications and azithromycin is most commonly chosen by doctors to treat a variety of bacterial infections.

One of the factors that made Zithromax so popular was the fact that it could be taken as a five-day treatment while most other antibiotics are prescribed to be taken over a 10-day treatment plan.

“The fact that there were so many individuals included in this massive research study reported in the New England Journal of Medicine study and that the FDA is now reviewing this material has increased concerns by many consumers who are telling us that they were treated with this medication,” said Resource4thePeople.

“Therefore, our lawyers are now actively investigation these claims and stand ready to offer their experience in this area of the law to fully inform consumers who contact us about what facts must be proven in the filing of a Zithromax lawsuit over allegations of serious cardiovascular side effects.”

http://www.resource4thepeople.com/defectivedrugs/Zithromax-lawsuits.html

SOURCES:
*http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm304503.htm
** http://www.nejm.org/doi/full/10.1056/NEJMoa1003833

Read the full story at http://www.prweb.com/releases/2013/4/prweb10594126.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Zithromax Arrhythmia and Sudden Death Allegation Lawsuits Now Being Investigated by Resource4thePeople Lawyers
2. D'Oliveira & Associates Now Offers a No Win No Fee Promise in Zithromax Cases
3. Researchers use iPSCs to define optimal treatment for managing life-threatening arrhythmias
4. Predicting risk of arrhythmias and sudden cardiac death: Theres a computer model for that
5. ESC analysis reveals arrhythmia treatment gaps between Eastern and Western Europe
6. Fine tuning cardiac ablation could lead to quicker results for patients with arrhythmias
7. Beaumont doctors call for training to reduce sudden cardiac arrest fatalities in schools
8. Sudden death in young athletes: Important causes not identified by the screening process
9. ECG screening for competitive athletes would not prevent sudden death
10. Fish oil may protect dialysis patients from sudden cardiac death
11. Miami Injury Attorneys Reacts to Toyota's Decision to Settle High-Profile Sudden Acceleration Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host ... honoring the 2016 MPN Heroes—eight individuals who have made a difference in the field ... the standard of care, demonstrating leadership within the MPN community and/or a commitment to ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 ... hydroxyurea (HU) in Complete Hematologic Response (CHR) ... ropeginterferon alfa-2b versus HU AOP will submit ... CONTINUATION-PV to obtain European marketing authorization in the coming months ... the FDA as it seeks approval for commercialization in the ...
(Date:12/4/2016)... 2016 Sickle cell disease (SCD) is an ... cells that get stuck in veins and block blood ... and complications leading to death. Each year, approximately 300,000 ... most of them lack access to comprehensive care or ... therapy for SCD, a pill called hydroxyurea approved more ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology: